Clinical evaluation of the antiarrhythmic properties of intravenously administered mexiletine: Efficacy comparison with lidocaine in a crossover randomized trial

B. Trimarco, B. Ricciardelli, M. Volpe

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty patients with stable ventricular arrhythmias participated in a cross-over study based on intravenous mexiletine and lidocaine for three consecutive days. Efficacy was assessed by long-term tape recordings of electrocardiogram. After a two-hour control period, the patients received one of the two drugs, according to a randomized scheme, for 24 hours. Then, a wash-out period of 22 hours was allowed, followed by a second control period of 2 hours. Afterwards, a cross-over to the other drug was performed. Both drugs reduced significantly the number of ventricular extrasystoles per minute but the reduction induced by mexiletine was more marked (86 ± 6% versus 68 ± 5%, p <0.05). Arrhythmia control (greater than 75% reduction of premature ventricular complexes) was achieved in 27 trials with mexiletine and 25 with lidocaine. No significant difference between the two drugs was observed in the incidence of adverse reactions. These results indicate that mexiletine is at least as effective and safe as lidocaine for suppression of ventricular arrhythmias and may be useful also in some cases of lidocaine-resistant dysrhythmias.

Original languageEnglish
Pages (from-to)370-378
Number of pages9
JournalCurrent Therapeutic Research
Volume29
Issue number3 I
Publication statusPublished - 1981

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Clinical evaluation of the antiarrhythmic properties of intravenously administered mexiletine: Efficacy comparison with lidocaine in a crossover randomized trial'. Together they form a unique fingerprint.

Cite this